



Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI)

R. Lo Dico, M. Faron, Y. Yonemura, O. Glehen, M. Pocard, A. Sardi, M. Hübner, D. Baratti, G. Liberale, A. Kartheuser, et al.

► To cite this version:

R. Lo Dico, M. Faron, Y. Yonemura, O. Glehen, M. Pocard, et al.. Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI). *EJSO - European Journal of Surgical Oncology*, 2021, 47, pp.89 - 100. <10.1016/j.ejso.2020.07.038>. <hal-03493675>

HAL Id: hal-03493675

<https://hal.science/hal-03493675v1>

Submitted on 2 Jan 2023

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons CC BY-NC 4.0 - Attribution - Non-commercial use - International License

Type of article: **Original Article**

Title of article:

Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a Worldwide Analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI)

Running head:

Extended surgical approach for liver and peritoneal metastases from colorectal cancer

Authors:

R. Lo Dico¹, M. Faron², Y. Yonemura³, O. Glehen³, M. Pocard¹, A. Sardi⁵, M. Hübner⁶, D. Baratti⁷, G. Liberale⁸, A. Kartheuser⁹, I. de Hingh¹⁰, P. Sugarbaker¹¹, W. Ceelen¹², B. Moran¹³, M. Robella¹⁴, F. Quenet¹⁵, L. Sideris¹⁶, D. Goere², M. Limbert¹⁷, P. Sammartino¹⁸, and D. Morris¹⁹ PSOGI Working Group, BIG RENAPE Working Group

Affiliations:

¹ Department of Digestive and Oncological Surgery, Lariboisière Hospital, AP-HP; INSERM Unit U1275 / CAP Paris-Tech: CArcinose Péritoine Paris-Technologies, Université Sorbonne Paris Cité, Paris, France

² Department of Visceral and Oncological Surgery, Gustave Roussy, Villejuif, France

³ Peritoneal Surface Malignancy Center, Kishiwada Tokushukai Hospital, 4-27-1 Kamori-Cho, Kishiwada City, Osaka, 596-8522, Japan

⁴ Department of Surgical Oncology, Hospices Civils de Lyon, Lyon Sud Hospital, Faculty of Medicine, France

⁵ The Institute for Cancer Care, Mercy Medical Center, Baltimore, MD, USA.

⁶ Department of Visceral Surgery, Lausanne University Hospital (CHUV), University of Lausanne (UNIL), Switzerland

⁷ Peritoneal Surface Malignancies Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

⁸ Department of Surgery, Institut Jules Bordet, Université Libre de Bruxelles, Belgium

⁹ Department of Abdominal Surgery and Transplantation, Colorectal Surgery Unit, Saint-Luc University Hospital, Université Catholique de Louvain (UCL), Belgium

¹⁰ Department of Surgery, Catharina Hospital, P.O. Box 1350, 5602 ZA, Eindhoven, Netherlands

¹¹ Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, 106 Irving Street NW, Suite 3900, Washington, DC, 20010, USA

¹² Department of Gastrointestinal Surgery, Ghent University Hospital, Belgium

¹³ Peritoneal Malignancy Institute Basingstoke, Hampshire Hospitals Foundation Trust, Adelmaston Road, Basingstoke, RG24 9NA, UK

¹⁴ Unit of Surgical Oncology, Candiolo Cancer Institute, IRCCS - FPO, Candiolo, Italy

¹⁵ Department of Surgery, Montpellier Cancer Institute, France

¹⁶ Department of Surgery, Hospital Maisonneuve-Rosemont, University de Montreal, Quebec, Canada

¹⁷ IPO, Cirurgia Geral e Proctologia, Hospital Lusíadas Lisboa, Portugal

¹⁸ Department of Surgery Pietro Valdoni, Sapienza University of Rome, Italy

¹⁹ Department of Surgery, Peritonectomy Center, St George Hospital, Gray St Kogarah, Sydney, NSW, 2217, Australia

PSOGI Working Group and BIG-RENAPE Working Group

The collaborators of the BIG-RENAPE Working Group are listed in Acknowledgements and include the following:

J. Abba (Department of Surgical Oncology, CHU Grenoble University, Grenoble, France); K. Abboud (Department of General Surgery, Centre Hospitalier Universitaire, Jean Monnet University, Saint Étienne, France); C. Arvieux (Department of Surgical Oncology, CHU Grenoble University, Grenoble, France); S. Carrere (Department of Surgical Oncology, Institut du Cancer de Montpellier, Montpellier, France); O. Facy (Department of Surgical Oncology, CHU Dijon, Dijon, France); G. Ferron (Department of Surgical Oncology, IUCT Oncopole, Toulouse, France); G. Lorimier (Department of Surgical Oncology, ICO-Paul Papin, Angers, France); F. Marchal (Department of Surgical Oncology, Institut de Cancerologie de Lorraine, Vandoeuvre-les-Nancy, France); P. Ortega-Deballon (Department of Surgical Oncology, CHU Dijon, Dijon, France); P. Rat (Department of Surgical Oncology, CHU Dijon, Dijon, France); J.-J. Tuech (Department of Digestive Surgery, Charles Nicolle University Hospital, Rouen, France), Laurent Villeneuve (Department of Surgical Oncology, Hospices Civils de Lyon).

Corresponding author:

Rea Lo Dico, MD, PhD

¹Department of Digestive and Oncological Surgery, Lariboisière Hospital, AP-HP, Paris,
France

INSERM Unit U1275 / CAP Paris-Tech: CArcinose Péritoine Paris-Technologies, Paris,
France

Université Sorbonne Paris Cité

75010 Paris, France

Tel: +33 1 49 95 84 34

Fax: +33 1 49 95 91 02

e-mail: rea.lo-dico@aphp.fr

Conflicts of interest: None to declare

Sources of support: No funding - No financial relationships

Study concepts: LO DICO Rea

Study design: LO DICO Rea, POCARD Marc, MORRIS David, SAMMARTINO Paolo

Data acquisition: LO DICO Rea

Quality control of data and algorithms: LO DICO Rea, SAMMARTINO Paolo,
POCARD Marc

Data analysis and interpretation: all authors

Statistical analysis: FARON Mathieu, LO DICO Rea

Manuscript preparation: all authors

Manuscript editing: all authors

Manuscript review: all authors

Combined Liver Resection and Cytoreductive Surgery with HIPEC for metastatic colorectal cancer: Results of a Worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI)

INTRODUCTION

A curative approach in patients with oligometastatic colorectal cancer can achieve "better than expected" long-term survival and provides the rationale for an extensive surgical approach in case of metastases limited in number and to one or a few organs¹.

Liver metastases (LM) occur in 25–40% of patients with colorectal cancer (CRC)². The long-term outcomes of patients with LM undergoing systemic chemotherapy alone is poor, with a median overall survival (OS) of 16 months as reported in the Cairo trial³, and up to 31 months with treatment intensification as shown in the TRIBE trial⁴. A meta-analysis by *Franko et al.* reported an OS of 19 months in patients with LM from CRC⁵. Curative management of LM is based on surgical resection, although in 70% of cases, LM will recur despite the use of multimodal and adjuvant chemotherapy².

Peritoneal metastases (PM) are present in 3.5-8.3% of patients with CRC at the time of diagnosis⁶⁻⁸, and are associated with poor survival, being as low as 6 months if left untreated⁹. The presence of isolated PM in patients with CRC is prognostic of poor OS compared with isolated non-peritoneal metastases⁵. Using modern systemic chemotherapy, modest improvements in prognosis can be achieved with median OS in the range of 12–16 months^{5,10}. Cytoreductive surgery (CRS) with intraperitoneal chemotherapy, including hyperthermic intraperitoneal chemotherapy (HIPEC) has been proposed as the only potentially curative

treatment for PM of CRC origin, achieving a median OS of 31.6 months¹¹⁻¹². A median OS up to 41.7 months and a recurrence-free survival of 13.1 months and has also been recently reported in highly selected patients¹³. The National Comprehensive Cancer Network (NCCN) guideline recommends that complete CRS combined with HIPEC can be considered in high-volume centers for selected patients with limited peritoneal metastases in whom R0 resection can be achieved¹⁴.

Simultaneous LM and PM from CRC has traditionally been considered a contraindication to any surgical approach because this disease presentation has been associated with very poor survival^{15,16}. However, smaller pilot series have reported prolonged survival, reaching up to 3 years in selected patients, after management of simultaneous colorectal LM and PM with CRS plus HIPEC combined with liver resection (LR). The authors claim that LM were not an absolute contraindication to a curative surgical management of PM and the concomitant treatment of both might indeed be possible¹⁷⁻²⁵. However, to date, no standard management pathway has been established for patients with simultaneous LM and PM, especially if a major hepatectomy and extensive peritoneal CRS have to be performed. Moreover, there are currently no specific criteria to select patients with the highest potential for surgical success, nor guidelines concerning the timing of peritoneal and liver surgery.

The aim of this study was to assess the early outcomes and survival of CRC patients undergoing LR and peritoneal CRS with HIPEC for concomitant PM and LM. The secondary aim was to identify potential factors related to poorer outcomes, in order to establish a basis to guide the management of these patients, optimizing the selection of candidates for surgical treatment and determining the best sequence of surgical procedures.

PATIENTS AND METHODS

Data Collection

A prospectively maintained multi-institutional database was established using the PSOGI and BIG-RENAPE database networks from surgical teams of expert centers for colorectal PM performing CRS and HIPEC. This study was carried out in accordance with the precepts established by the Helsinki Declaration and the institutional review board for each center approved the study procedures. Using the databases of 33 international expert centers from 13 different countries, we identified and collected in a retrospective analysis all patients with concomitant PM and LM from CRC treated with LR and CRS with HIPEC between 1993 and 2017.

All background clinical, histological, operative and postoperative data for this study were prospectively collected, entered into a standardized central electronic database and analyzed retrospectively. We included only patients whose clinical records contained complete information such as age, Eastern Cooperative Oncology Group (ECOG) performance status, tumor markers, diagnostic techniques, AJCC stage group (VIII ed.) and histopathology of primary tumor, number and site of LM, surgical procedures used during CRS and LR including complications according to the Clavien-Dindo classification²⁶, Peritoneal Cancer Index (PCI)²⁷, completeness of cytoreduction (CC) score²⁷, HIPEC techniques and drugs, systemic chemotherapy and eventual drug-induced toxicity evaluated according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE version 4.0)²⁸ and last complete updated data on follow-up.

Indications for CRS plus HIPEC combined with LR were concomitant metastatic spread to peritoneum and liver from colorectal cancer in patients younger than 75 years of age with adequate cardiac, renal, hepatic and bone marrow function, ECOG performance status 0 to 1,

written informed consent, resectable disease and for the present study patients in whom CRS had a likelihood of achieving residual disease measuring at least < 2.5 mm (CC1). Contraindications for CRS plus HIPEC combined with LR were extra-abdominal disease, other malignancies, unresectable disease or patients with progressive disease after neoadjuvant chemotherapy and patients whose severe associated medical conditions made them unfit for the procedure. Ovarian metastases were considered a manifestation of peritoneal disease²⁹.

Operative treatment

Simultaneous resection was defined as LR and CRS plus HIPEC during the same operation (one step procedure) and separate procedures were defined as two-steps procedures. Detailed staging and evaluation of systemic chemotherapy eventually combined with biological or molecular treatment depended mainly on imaging findings including computed tomography (CT), magnetic resonance imaging (MRI) and positron emission CT (PET-CT). Staging laparoscopy was used mainly for histopathological sampling or when imaging failed to specify resectability. Patients were scheduled for CRS combined with HIPEC and LR according to a likelihood of achieving complete peritoneal cytoreduction (CC0/1) and LR, and dependent on the patient's general condition following discussion at a multidisciplinary meeting including surgeons, medical oncologists, and dedicated radiologists at each PSM center

At laparotomy, the peritoneal spread was recorded according to the PCI²⁷. Patients then underwent surgery with curative intent: CRS of peritoneal disease was performed with peritonectomy and visceral resection according to standardized procedure, albeit some surgical techniques may have varied among centers. Visceral resections and the other peritonectomy procedures were done depending on the distribution of malignancy in the peritoneal space; normal peritoneum was never excised. If macroscopically affected, the

appendix and ovaries were systematically removed. HIPEC was administrated after completion of CRS using an open coliseum or closed technique according to the team's preference, to deliver the chemotherapy agent at 42-43°C for 30-90 min in a closed circuit. The drugs employed and the duration of the intra-peritoneal chemotherapy was previously described³⁰⁻³¹.

LR was performed according to the principles of oncologic radicality. Minor hepatectomy was defined as any LR of less than three hepatic segments, including atypical resection (metastasectomy, segmentectomy and bisegmentectomy), and radiofrequency ablation (RFA) for lesions measuring less than 2.5 cm and located far from the main vessels according to each team's preference. Major hepatectomy was defined as the LR of at least three hepatic segments, minor resection was defines as the segmentectomies (anatomical resections) and local ablation was defines as non-anatomical or limited resections (wedge resections, radiofrequency or cryotherapy).

Postoperative complications was defined as taking place within 90 days after surgery and operative mortality as death within 90 days after surgery or until hospital discharge. For 2-staged surgeries we added up the length of stay for both hospital admissions.

The general approach across the centers was that patients requiring minor resections had simultaneous LR and peritoneal CRS and HIPEC, whereas in some cases major LR and CRS and HIPEC was performed in two steps: liver-first approach, when the LR was followed by CRS and HIPEC, and delayed LR when the CRS and HPEC was the first procedure.

Endpoints

The primary endpoint of the analyses was OS. OS was defined as the time from diagnosis of liver or peritoneal metastases to the time of death due to any cause. The secondary endpoints were relapse-free survival (RFS), postoperative morbidity/mortality at 90 days according to

the Clavien-Dindo classification²⁶, and duration of hospital stay. RFS was defined as the time from first surgery, CRS and HIPEC or LR, to relapse, or death, whichever occurred first. RFS at 3 years was defined as the percentage of patients that were relapse-free at three years. In the case of two-steps procedures, the first surgical procedure date was considered as the first treatment day. Second colorectal cancers were considered as RFS events, whereas non-colorectal tumors were disregarded in the analyses.

Statistical Analysis

Quantitative variables were described as mean (+/- standard deviation) or median (inter quartile range) depending on the distribution and compared with Student's t-test or Wilcoxon's test. Qualitative variables were described as count (percentage) and compared with Chi square test or Fisher's exact test as appropriate.

Survival curves were calculated according to Kaplan-Meier and compared with the log-rank test. Median follow-up was calculated according to Schemper's method³².

The Cox proportional hazard model was used to determine factors influencing patient prognosis. Any variable achieving a $p < 0.2$ in the univariable analysis was then entered in a Cox multivariable model. Backward variable selection based on Akaike's Information Criteria (AIC) was used to identify the subset of independent variables.

RESULTS

Patient Characteristics

Five hundred and sixty-five consecutive patients from 33 centers were screened (Fig. 1). Four hundred and ninety-one patients (91.9%) were treated with preoperative systemic chemotherapy before surgery given to treat PM and/or LM before CRS/HIPEC and LR. The average interval between diagnosis of liver or peritoneal metastases and combined surgery was 6 months. For 224 patients (41.9%), the PM were synchronous with the primary tumor, for 206 (38.6%) LM were synchronous with the primary tumor. Regarding the first choice of IP chemotherapy during HIPEC, oxaliplatin (55%), mitomycin-C (37%), and “other” (8%), were reported. Patient characteristics are summarized in Tables 1.

Treatment Related Data

Median PCI was 9.8 (SD: 7.4, range, 0-39), being ≥ 12 in 152 patients (Table 2). A complete CRS (CCR-0-1) was achieved in 534 (94.7%) patients. Four hundred and thirty seven patients (81.8%) underwent LR simultaneously with CRS and HIPEC, whereas 97 (18.2%) had two-steps procedures, among them 66 (12%) had liver-first approach (Fig. 1). The median number of LM was 2 (IQR: 1-3, range: 1–14). Major LR was performed in 41 patients (7.3%); forty-five patients (8.4%) were treated with minor resection, and 337 (63.1%) with local ablation or with the association of two or more limited resections (Table 2).

Early Outcome

The overall severe postoperative complications (grades III-IV) occurred in 176 patients (32.9%) and surgical interventions for complications were required in 80 patients (15%). The

overall postoperative mortality rate was 4.0% (n=23). Severe complications occurred in 141/437 (32.3%) patients who underwent a one-step procedure, and in 35/97 (35.7%) who underwent two-steps procedures. Briefly: if a liver-first approach was chosen, we observed 6 severe complications after LR (6.1%) and 21 after CRS and HIPEC surgery (21.6%); for patients receiving delayed LR we observed 6 complications after CRS and HIPEC surgery (6.1%) and 2 after LR (2.1%). The median duration of hospital stay was 24 days (SD: 14.6, range, 5-152 days). Simultaneous CRS and LR was associated with a shorter postoperative hospital stay than two-steps procedures (23 (SD:14.4) vs. 30 (SD: 23.0) days, respectively, $P=0.1$) (Table 3). In case of two-steps procedures the durations of the two stays were added to obtain a cumulative stay. The number of LM and the type of LR were not identified as being associated with the frequency of severe postoperative complications (Table 4).

Long-term Outcome

The median follow-up was 48.4 months (95% CI 44.2-56.2). The median OS was 47.6 months (95% CI 42.5-53.3), with 1-, 3- and 5-year OS rates being 93%, 64% and 39% respectively (Fig. 2). The median RFS was 19.4 months (95% CI, 17.4-20.7), with 1-, 2- and 3-year RFS rates being 74%, 37%, and 21% respectively (Fig. 2). For patients who underwent preoperative chemotherapy (91.9%), the average interval between diagnosis of liver or peritoneal metastases and combined surgery was 6 months. Four hundred and sixteen (77.9%) patients had a recurrence during the follow-up. The liver was the most frequent site of recurrences 41.1% (n=231). Among this group, 62/231 (27%) had isolated liver recurrence. Fifty-four (10%) patients had isolated peritoneal recurrence, 213 (39.9%) patients had extra-peritoneal recurrence, and 143 (26.8%) patients had both. Among the patients with extra-

abdominal recurrence, 138 (24.4%) had pulmonary metastases, either isolated or in combination with other sites. Overall, 282 (49.9%) patients died during the follow-up period. The sequence of the surgery had an impact on the survival (Fig. 3A and B). For patients treated with liver-first approach, the median OS and RFS were better than patients treated with CRS and HIPEC first or for patients who had one-step procedure (63.7, 52.6 and 44.8 months respectively for OS ($P= 0.036$), and 28.2, 17.1 and 17.8 for RFS, ($P= 0.016$)). Upon univariate analysis, PCI, adjuvant LR chemotherapy and surgical sequence, were identified as prognostic factors for lower OS. Moreover, our results have shown a trend towards a lower OS after use of different than oxaliplatin-based drugs for IP compound and modern systemic chemotherapy. At multivariate analysis, only PCI remained as a significant prognostic factor (Table 5). Kaplan-Meier curves for OS of all patients and stratified by surgical sequence are shown (Fig 3A). At univariate analysis, higher PCI and surgical sequence were both identified as greater prognostic factors for lower RFS than primary tumor side. These results were confirmed on multivariate analysis (Table 6). The Kaplan-Meier curves of all RFS patients, stratified by surgical sequence, are shown in Fig 3B.

DISCUSSION

The management of patients with liver and peritoneal metastases from CRC has undergone major improvements over the past few decades. Whereas OS did not exceed one year with classic systemic chemotherapy based on 5-FU³³, oxaliplatin and targeted therapies such as anti-angiogenic or anti-EGFR antibodies (for wild type *RAS*) have allowed extending the OS up to 2 years in selected patients^{5,20,34}. Recent studies have suggested that resection of liver and peritoneal metastases, combined with HIPEC, may increase OS up to 3 years, despite an increased risk of morbidity^{17,19}. Recently, the combination of three systemic chemotherapy agents (FOLFOXIRI regimen) has shown an increased OS of several months in metastatic CRC patients compared to classical chemotherapy regimens⁴, and some achieve OS similar to extensive surgery. However, the incidence of serious adverse events in patients treated with FOLFOXIRI plus bevacizumab is up to 20.4%³⁵, which is comparable to perioperative morbidity of major surgery (5-28% for CRS and HIPEC¹⁶ and 5-20% for major liver resection)³⁶⁻³⁸.

This multicenter study is the largest series of selected patients with PM from CRC and simultaneous LM treated with LR, CRS and HIPEC. The present study shows that extended surgical management of multi-metastatic CRC is feasible with an acceptable morbidity and reasonably low postoperative mortality rates (31% and 4%, respectively). These morbidity and mortality rates are consistent with those reported after LM resection and similar to PM treatment alone^{13,17,23,34}. We believe these low rates of morbidity were achieved by careful selection of patients: if LM required only minor LR, this was usually performed at same time as CRS + HIPEC. However, if LM required complex or major LR, especially in patients with suspected liver parenchyma damage through preoperative chemotherapy, resection of LM was mostly performed non-simultaneously to CRS and HIPEC. Interestingly, despite this

approach, a major LR was not associated with an increased complication rate compared with minor LR. However, we suggest that this concept of two-steps procedures, already used in complex abdominal and liver surgeries, may represent a valuable tool to reduce patient morbidity and mortality rates. Despite this cautionary note, In light of the present data, it should be concluded that when both LM and PM are resectable, extended surgery improves chances for selected patients to achieve favorable OS rates. Surprisingly, in this study, we found that for patients treated with liver first approach the median RFS was significantly better than other surgical sequence strategies. In order to further discuss available surgical sequence strategies³⁹ to be advocated in case of advanced CRC (liver metastases) with asymptomatic primary, a recent meta-analysis⁴⁰ demonstrated that no significant differences in long-term survival and major morbidity were found amongst the simultaneous, delayed and liver-first approach. Moreover, the reverse strategy (so-called liver-first approach) was ranked as the potentially best treatment with respect to its relative efficacy on the basis of 5-year OS outcomes and postoperative complication rate compared to simultaneous or delayed LR. Probably because the risk that LM becomes unresectable during the interval between two surgeries is real, some centers have chosen to realize liver-first approach. The better OS and RFS rates between the different strategies showed in this study suggested that the liver-first approach strategy might be an appropriate option for the surgical sequencing of this select group of patients. However, this conclusion is in contrast with the results obtained with the only experimental model known to assess PM growth after LR⁴¹. Furthermore, the patients who had liver-first approach and then never went on to receive CRS and HIPEC, because of the progression, are not included in the analysis. Thus, the cohort of patients treated by liver-first approach and then by CRS and HIPEC represents a highly selected population of patients with better biology than those who never progress to the second step procedure. Limited peritoneal disease extent should be an advantage to explain better survival after liver first

approach. Should be possible that the survival advantage was not related to the surgical sequence but to lower peritoneal tumor load. However, as shown in table 2, the difference between PCI values in function of the surgical sequence is very low and does not explain the result. More investigations are necessary in order to conclude.

A limitation of this study is the period of data collection from numerous institutions during which temporal trends such as the advent of modern systemic chemotherapy has also taken place. To minimize this bias, the analysis was stratified by time periods (before and after 2000) to discern the effect of modern oxaliplatin-based. No impact in OS and RFS was observed in the limited sample of only 56 (10%) of patients were treated with extended surgical approach before 2003. However, the small sample size could explain the non-significance of the result.

Despite the encouraging OS rates in our study, almost 50% of patients recurred within the first eighteen postoperative months. We also found an association between reduced RFS and severe complication events (HR = 1.19 [IC 95% 0.98-1.44], p = 0.081), which is in line with previous studies⁴². However, we also found that OS was surprisingly not related to severe morbidity as an earlier recurrence was assumed to be related to shorter survival. *Varban et al.* have also reported similar results³⁴. Thus, these data suggest that careful selection of patients, less likely to experience severe postoperative complications, may allow for improved RFS. Nevertheless, the association of complications and survival should be attentively considered when selecting any patient with LM and PM for surgery.

The promising long-term results of LM surgery from CRC over the past decade and recent trends towards increasing surgical aggressiveness (as illustrated by iterative resections of LM)⁴³ have formed the rationale for the surgical management of both LM and PM, given that CRS + HIPEC may also achieve excellent outcomes. Some series suggest that relatively long survival may be achieved with aggressive management, including the simultaneous resection

of LM and PM^{19,44,45}. Previous findings were confirmed in the present study showing that OS is significantly prolonged up to 60 months in selected cases. However, a meta-analysis of *de Cuba et al.* showed that patients with synchronous PM and LM of CRC seemed to fare less well when compared to patients with isolated PM (pooled HR=1.24, 95%CI 0.96–1.60)²⁰. Despite this, the authors also showed a tendency towards better OS in carefully selected patients with PM and LM who were treated with curative resection of both sites plus HIPEC compared to treatment with modern systemic chemotherapy alone.

The PCI is considered the most widely used tool to evaluate disease extent in peritoneal surface malignancies^{16,46-48}. Increased PCI is also recognized as an independent prognostic indicator for long-term outcomes in patients with PM from CRC⁴⁹ and an inverse linear relationship between any point rise in PCI and OS has been demonstrated⁵⁰. Similarly, we found that PCI was an independent prognostic factor for OS and RFS in patients undergoing simultaneous resection of LM and PM. This result is in line with previous Italian two-center study reporting worse outcomes in patients with peritoneal than non-peritoneal colorectal metastases. However, survival benefit may be obtained in selected patients with limited peritoneal involvement⁵¹. Whilst PCI also influences the likelihood of complete cytoreduction^{11,52}, in the present analysis, the quality of CRS was optimal in close to 95% of the patients, with a reasonable mean PCI of about 10. This finding is in line with the literature, as previous studies have shown that a large volume of disease was associated with poor long-term survival even if complete cytoreduction was achieved^{47,49}.

The concomitant presence of LM is considered a poor prognostic factor compared to patients with PM alone^{16,20,45}. *Elias et al.* reported that completely resected LM during CRS remained a negative prognostic factor for patients with PM of CRC⁵³. However, *Maggiori et al.* suggested that in LM and PM, prolonged survival may still be achieved in highly selected patients with limited peritoneal disease (PCI <12)⁴⁴. In our study, we also found that a

PCI>12 was associated with a poor OS in both uni- and multivariate analysis. Therefore, the PCI itself could be a useful criterion for patient selection. In line with *de Cuba et al.*, we also believe that, based on current data, there is no evidence to support an exclusion of patients with PM and LM from aggressive, potentially curative treatment²⁰. However, an accurate, extensive preoperative evaluation is mandatory before surgery, and thus a diagnostic laparoscopy may prove useful in avoiding unnecessary surgery in high PCI and simultaneous CRC LM patients⁵⁴.

The recent results of the PRODIGE 7¹³, a prospective randomized multicenter phase III French trial, reopen the question concerning the benefit on survival outcomes given by the addition of HIPEC to the CRS compared to the CRS alone. Is it thus possible that CRS plus LR without HIPEC could have the same results of survival outcomes and lesser morbidity rates compared to the CRS plus LR with HIPEC? CRS plus LR without HIPEC has been reported in only rare and small series^{55,56}. *Allard et al.* showed that combined resection of LM and limited peritoneal deposits (median PCI: 2) accidentally discovered intra-operatively was associated with an 18% of 5-year OS rate and a median OS of 42 months⁵⁶. However, in our study combined resection of LM and PM with HIPEC is associated with a better OS of 47 months with 5-year OS rates being 38% in patients with a higher PCI (median PCI: 10). These better results are probably associated with a better selection of patients and the intrinsic properties of IP chemotherapy: the cytotoxic effects to the hyperthermia and the high local concentration compared to the systemic chemotherapy. Our conclusion is that the option of resection without HIPEC may potentially be proposed in cases where there is concern that HIPEC may increase in morbidity.

Currently, two regimens are widely used open-abdomen Oxaliplatin ± Irinotecan with concurrent intravenous 5-fluorouracil and folinic acid, and open- or close-abdomen Mitomycin-C, alone or in combination with other drugs¹². In this series we found that the use

of Oxaliplatin vs other IP regimens had better outcomes. The improvement on the OS of the PM from CRC using modern Oxaliplatin-based chemotherapies is known. The role of the IP Oxaliplatin remains unclear. As previously reported most cytoreductive surgeons doing HIPEC with Oxaliplatin carried out the hyperthermic perfusion only for 30 min, and most of those doing HIPEC with MMC did it for 90 min. It is possible that the duration of hyperthermia, and not the drug itself could be responsible for survival difference⁵⁷. However, in the same study patients considered with negative prognostic factors had better results in terms of survival if treated with IP Oxaliplatin. We considered that the presence of two metastatic sites, liver and peritoneum, in our population is a prognostic factor and this would explain the better result if treated with Oxaliplatin.

Despite analyzing prospectively maintained databases, this study is limited by its retrospective design resulting in some missing data. Furthermore, great heterogeneity in patient selection and operative techniques may have compromised our findings. However, despite these short-comings, this study represents the largest multicenter series, to date, and the data provided herein forms a basis for future prospective trials.

CONCLUSION

This multicenter study demonstrated the feasibility of the simultaneous treatment of colorectal cancer dissemination to the liver and peritoneum with liver resection, cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in combination to systemic chemotherapy in selected patients, resulted in a 48-month median overall survival, with reasonable morbidity. Even though this study suggests performing liver-first approach in the case of two-steps procedures, the exact timing of these individual complex treatment steps remains unknown. Future studies assessing the feasibility of this surgical approach in a prospective, randomized setting, as well as further studies elucidating how best to control disease progression

following disease recurrence, would be helpful in improving the care of patients with advanced colorectal cancer.

REFERENCES

1. Hellman S, Weichselbaum RR.. Oligometastases.. *J Clin Oncol*. 1995 Jan;13(1):8-10.
2. Nordlinger B, Sorbye H, Glimelius B, et al: Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. *Lancet* 371:1007-16, 2008
3. Koopman M, Antonini NF, Douma J, et al: Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. *Lancet* 370:135-42, 2007
4. Cremolini C, Loupakis F, Antoniotti C, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. *Lancet Oncol* 16:1306-15, 2015
5. Franko J, Shi Q, Meyers JP, et al: Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. *Lancet Oncol* 17:1709-1719, 2016
6. Lemmens VE, Klaver YL, Verwaal VJ, et al: Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. *Int J Cancer* 128:2717-25, 2011
7. Segelman J, Granath F, Holm T, et al: Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. *Br J Surg* 99:699-705, 2012
8. van Gestel YR, Thomassen I, Lemmens VE, et al: Metachronous peritoneal carcinomatosis after curative treatment of colorectal cancer. *Eur J Surg Oncol* 40:963-9, 2014
9. Bengtsson G, Carlsson G, Hafstrom L, et al: Natural history of patients with untreated liver metastases from colorectal cancer. *Am J Surg* 141:586-9, 1981
10. Koppe MJ, Boerman OC, Oyen WJ, et al: Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. *Ann Surg* 243:212-22, 2006
11. Verwaal VJ, van Ruth S, de Bree E, et al: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. *J Clin Oncol* 21:3737-43, 2003
12. Baratti D, Kusamura S, Pietrantonio F, et al: Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review. *Crit Rev Oncol Hematol* 100:209-22, 2016
13. Quenet F, Elias D, Roca L, et al: A UNICANCER phase III trial of hyperthermic intra-peritoneal chemotherapy (HIPEC) for colorectal peritoneal carcinomatosis (PC): PRODIGE 7. *Journal of Clinical Oncology* 36:LBA3503-LBA3503, 2018
14. Tanaka T, Ozawa H, Nakagawa Y, Hirata A, Fujita S, Sugihara K. Verifying the M1c category of CRC: analysis of the data from a Japanese multi-institutional database. *Int J Colorectal Dis*. 2020 Jan;35(1):125-131
15. Fong Y, Fortner J, Sun RL, et al: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. *Ann Surg* 230:309-18; discussion 318-21, 1999
16. Glehen O, Kwiatkowski F, Sugarbaker PH, et al: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. *J Clin Oncol* 22:3284-92, 2004
17. Kianmanesh R, Scaringi S, Sabate JM, et al: Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases. *Ann Surg* 245:597-603, 2007
18. Izzo F, Piccirillo M, Palaia R, et al: Management of colorectal liver metastases in patients with peritoneal carcinomatosis. *J Surg Oncol* 100:345-7, 2009

19. Chua TC, Yan TD, Zhao J, et al: Peritoneal carcinomatosis and liver metastases from colorectal cancer treated with cytoreductive surgery perioperative intraperitoneal chemotherapy and liver resection. *Eur J Surg Oncol* 35:1299-305, 2009
20. de Cuba EM, Kwakman R, Knol DL, et al: Cytoreductive surgery and HIPEC for peritoneal metastases combined with curative treatment of colorectal liver metastases: Systematic review of all literature and meta-analysis of observational studies. *Cancer Treat Rev* 39:321-7, 2013
21. Berger Y, Aycart S, Tabrizian P, et al: Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with liver involvement. *J Surg Oncol* 113:432-7, 2016
22. Delhorme JB, Dupont-Kazma L, Addeo P, et al: Peritoneal carcinomatosis with synchronous liver metastases from colorectal cancer: Who will benefit from complete cytoreductive surgery? *Int J Surg* 25:98-105, 2016
23. Navez J, Remue C, Leonard D, et al: Surgical Treatment of Colorectal Cancer with Peritoneal and Liver Metastases Using Combined Liver and Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Report from a Single-Centre Experience. *Ann Surg Oncol* 23:666-673, 2016
24. Lorimier G, Linot B, Paillocher N, et al: Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer. *Eur J Surg Oncol* 43:150-158, 2017
25. Pinto A, Hobeika C, Philis A, et al: Synchronous liver metastases and peritoneal carcinomatosis from colorectal cancer: different strategies for curative treatment? *Langenbecks Arch Surg* 404:477-488, 2019
26. Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 240:205-13, 2004
27. Jacquet P, Sugarbaker PH: Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. *Cancer Treat Res* 82:359-74, 1996
28. Basch E, Reeve BB, Mitchell SA, et al: Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). *J Natl Cancer Inst* 106, 2014
29. Evers DJ, Verwaal VJ: Indication for oophorectomy during cytoreduction for intraperitoneal metastatic spread of colorectal or appendiceal origin. *Br J Surg* 98:287-92, 2011
30. Brigand C, Monneuse O, Mohamed F, et al: Peritoneal mesothelioma treated by cytoreductive surgery and intraperitoneal hyperthermic chemotherapy: results of a prospective study. *Ann Surg Oncol* 13:405-12, 2006
31. Elias D, Goere D, Dumont F, et al: Role of hyperthermic intraoperative peritoneal chemotherapy in the management of peritoneal metastases. *Eur J Cancer* 50: 332-340, 2014
32. Schemper M, Smith T: A note of quantifying follow-up in studies of failure time. *Controlled Clinical Trials* 17:343-346; 1999
33. Thomassen I, van Gestel YR, Lemmens VE, et al: Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. *Dis Colon Rectum* 56:1373-80, 2013
34. Varban O, Levine EA, Stewart JH, et al: Outcomes associated with cytoreductive surgery and intraperitoneal hyperthermic chemotherapy in colorectal cancer patients with peritoneal surface disease and hepatic metastases. *Cancer* 115:3427-36, 2009
35. Loupakis F, Cremolini C, Masi G, et al: Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. *N Engl J Med* 371:1609-18, 2014
36. Imamura H, Seyama Y, Kokudo N, et al: One thousand fifty-six hepatectomies without mortality in 8 years. *Arch Surg* 138:1198-206; discussion 1206, 2003
37. Jarnagin WR, Gonen M, Fong Y, et al: Improvement in perioperative outcome after hepatic resection: analysis of 1,803 consecutive cases over the past decade. *Ann Surg* 236:397-406; discussion 406-7, 2002
38. Sano T, Shimada K, Sakamoto Y, et al: One hundred two consecutive hepatobiliary resections for perihilar cholangiocarcinoma with zero mortality. *Ann Surg* 244:240-7, 2006

39. Adam R, de Gramont A, Figueras J, et al: Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus. *Cancer Treat Rev* 41:729-41, 2015
40. Gavriilidis P, Katsanos K, Sutcliffe RP, et al: Simultaneous, Delayed and Liver-First Hepatic Resections for Synchronous Colorectal Liver Metastases: A Systematic Review and Network Meta-Analysis. *J Clin Med Res* 11:572-582, 2019
41. Lo Dico R, Tijeras-Raballand A, Bonnin P, et al: Hepatectomy increases metastatic graft and growth in an immunocompetent murine model of peritoneal metastases. *Eur J Surg Oncol* 44:784-791, 2018
42. Simkens GA, van Oudheusden TR, Luyer MD, et al: Serious Postoperative Complications Affect Early Recurrence After Cytoreductive Surgery and HIPEC for Colorectal Peritoneal Carcinomatosis. *Ann Surg Oncol* 22:2656-62, 2015
43. Taylor A KG: Survival after surgical resection of hepatic metastases from colorectal cancer: A systematic review and meta-analysis. *Ann Oncol* 21 Suppl 8:632, 2010
44. Maggiori L, Goere D, Viana B, et al: Should patients with peritoneal carcinomatosis of colorectal origin with synchronous liver metastases be treated with a curative intent? A case-control study. *Ann Surg* 258:116-21, 2013
45. Elias D, Faron M, Goere D, et al: A simple tumor load-based nomogram for surgery in patients with colorectal liver and peritoneal metastases. *Ann Surg Oncol* 21:2052-8, 2014
46. Koh JL, Yan TD, Glenn D, et al: Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. *Ann Surg Oncol* 16:327-33, 2009
47. Pestieau SR, Sugarbaker PH: Treatment of primary colon cancer with peritoneal carcinomatosis: comparison of concomitant vs. delayed management. *Dis Colon Rectum* 43:1341-6; discussion 1347-8, 2000
48. Shehata M, Chu F, Saunders V, et al: Peritoneal carcinomatosis from colorectal cancer and small bowel cancer treated with peritonectomy. *ANZ J Surg* 76:467-71, 2006
49. da Silva RG, Sugarbaker PH: Analysis of prognostic factors in seventy patients having a complete cytoreduction plus perioperative intraperitoneal chemotherapy for carcinomatosis from colorectal cancer. *J Am Coll Surg* 203:878-86, 2006
50. Faron M, Macovei R, Goere D, et al: Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer. *Ann Surg Oncol* 23:114-9, 2016
51. Baratti D, Kusamura S, Iusco D, et al: Should a History of Extraperitoneal Disease Be a Contraindication to Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Cancer Peritoneal Metastases? *Dis Colon Rectum* 61:1026-1034, 2018
52. Yan TD, Chu F, Links M, et al: Cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma: non-mucinous tumour associated with an improved survival. *Eur J Surg Oncol* 32:1119-24, 2006
53. Elias D, Gilly F, Boutitie F, et al: Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. *J Clin Oncol* 28:63-8, 2010
54. Najah H, Lo Dico R, Dohan A, et al: A feasibility study of the use of computed virtual chromoendoscopy for laparoscopic evaluation of peritoneal metastases. *Surg Endosc* 31:743-751, 2017
55. Desolneux, G Maziere C, Vara J: Cytoreductive surgery of colorectal peritoneal metastases: outcomes after complete cytoreductive surgery and systemic chemotherapy only. *PLoS One*. 2015 Mar 31;10(3):e0122816.
56. Allard MA, Adam R, Ruiz A et al: Is unexpected peritoneal carcinomatosis still a contraindication for resection of colorectal liver metastases? ^[T]_[SEP] Combined resection of colorectal liver metastases with peritoneal deposits discovered intra-operatively. *EJSO* 39 (2013) 981e987
57. Prada-Villaverde A, Esquivel J, Lowy AM, et al: The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. *J Surg Oncol*. 2014 Dec;110(7):779-85.

Fig. 1: Flow Chart of patient selection and study groups selected for analysis of concomitant liver and peritoneal metastases from colorectal cancer (CRC) treated by Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) associated with Liver resection (LR). LM, liver metastases; PM, peritoneal metastases; CCR, completeness of cytoreductive resection; * Data from the global population; **Second surgical procedure for post-operative complications




Fig. 2 : Kaplan–Meier curve for Overall Survival and Relapse Free Survival in patients undergoing combined liver resection and cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for concomitant colorectal liver and peritoneal metastases.




Fig. 3: Kaplan–Meier curve for Overall Survival (A) and Relapse Free Survival (B) in patients undergoing combined liver resection and cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for concomitant colorectal liver and peritoneal metastases by surgical sequence. One step (procedure) was defined as liver resection and cytoreductive surgery and hyperthermic intraperitoneal chemotherapy during the same operation; Liver-first (approach) when the liver resection was followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, HIPEC-first when liver resection was delayed.




Table 1. Demographics and characteristics of primary tumor of patients with liver and peritoneal metastases from colorectal cancer treated by cytoreductive surgery and hypertermic intraperitoneal chemotherapy associated with liver resection.

	ALL	One step	Liver first	HIPEC first	p-value
Age	54.8 (+/- 11.7)	54.89 (+/- 11.9)	54.6 (+/- 10.2)	54.55 (+/- 12.1)	0.98
Age >60					0.82
No	329 (63.3%)	269 (62.7%)	41 (65.1%)	19 (67.9%)	
Yes	191 (36.7%)	160 (37.3%)	22 (34.9%)	9 (32.1%)	
Gender					0.3
Female	312 (58.5%)	248 (57%)	44 (66.7%)	20 (62.5%)	
Male	221 (41.5%)	187 (43%)	22 (33.3%)	12 (37.5%)	
Type of Surgery					0.17
Laparoscopy	84 (26.7%)	59 (24.6%)	19 (37.3%)	6 (25%)	
Laparotomy	231 (73.3%)	181 (75.4%)	32 (62.7%)	18 (75%)	
Tumor side					0.97
Right	177 (33.9%)	142 (33.4%)	22 (33.8%)	13 (40.6%)	
Left	271 (51.9%)	220 (51.8%)	35 (53.8%)	16 (50%)	
Rectum	67 (12.8%)	57 (13.4%)	7 (10.8%)	3 (9.4%)	
Multifocal	7 (1.3%)	6 (1.4%)	1 (1.5%)	0 (0%)	
T from the TNM					0.27
T1 or T2	14 (3.6%)	11 (3.6%)	3 (6%)	0 (0%)	
T3	190 (49.5%)	146 (47.2%)	29 (58%)	15 (60%)	
T4	180 (46.9%)	152 (49.2%)	18 (36%)	10 (40%)	
N from the TNM					0.38
N0	101 (23.3%)	76 (22.2%)	15 (25.9%)	10 (31.2%)	
N1	169 (39%)	130 (37.9%)	26 (44.8%)	13 (40.6%)	
N2 or N3	163 (37.6%)	137 (39.9%)	17 (29.3%)	9 (28.1%)	
Differentiation					0.075
Good	85 (21.7%)	65 (21.2%)	17 (30.4%)	3 (10.3%)	
Moderate	225 (57.4%)	174 (56.7%)	28 (50%)	23 (79.3%)	
Poor	82 (20.9%)	68 (22.1%)	11 (19.6%)	3 (10.3%)	
Mucinous					0.24
No	295 (81%)	223 (79.4%)	49 (89.1%)	23 (82.1%)	
Yes	69 (19%)	58 (20.6%)	6 (10.9%)	5 (17.9%)	
Synchronous PM					0.0017
no	317 (60.7%)	249 (58.5%)	50 (76.9%)	18 (58.1%)	
yes	205 (39.3%)	177 (41.5%)	15 (23.1%)	13 (41.9%)	
Adjuvant CT					0.29
No	134 (25.5%)	115 (26.9%)	12 (18.2%)	7 (21.9%)	
Yes	392 (74.5%)	313 (73.1%)	54 (81.8%)	25 (78.1%)	

Table 2. Characteristics of peritoneal and liver metastases of patients treated by cytoreductive surgery and hypertermic intraperitoneal chemotherapy associated with liver resection.

	All	One step	Liver first	HIPEC first	p-value
Peritoneal Metastases					
CEA pre HIPEC	28.4 (+/- 70.2)	24.34 (+/- 50.2)	44.75 (+/- 126)	42 (+/- 103)	0.097
CA19.9 pre HIPEC	79.9 (+/- 212.1)	88.34 (+/- 224)	30.79 (+/- 58.7)	86.51 (+/- 272)	0.31
Neoadjuvant CT pre-HIPEC					0.013
No	119 (22.8%)	86 (20.2%)	23 (34.8%)	10 (32.3%)	
Yes	404 (77.2%)	340 (79.8%)	43 (65.2%)	21 (67.7%)	
Monoclonal antibodies pre-HIPEC					0.87
No	376 (70.3%)	305 (69.8%)	48 (72.7%)	23 (71.9%)	
Yes	159 (29.7%)	132 (30.2%)	18 (27.3%)	9 (28.1%)	
PCI	9.8 (+/- 7.4)	10.07 (+/- 7.6)	9.077 (+/- 6.88)	7.552 (+/- 4.48)	0.15
PCI ≥12	152 (30.2%)	129 (31.5%)	19 (29.2%)	4 (13.8%)	0.13
CCR					<0.0001
0	472 (88.4%)	399 (91.3%)	46 (69.7%)	27 (87.1%)	
1	62 (11.6%)	38 (8.7%)	20 (30.3%)	4 (12.9%)	
Mucinous					0.15
No	304 (79.8%)	225 (77.9%)	55 (88.7%)	24 (80%)	
Yes	77 (20.2%)	64 (22.1%)	7 (11.3%)	6 (20%)	
EPIC					0.087
no	341 (91.2%)	268 (89.9%)	49 (96.1%)	24 (96%)	
yes	28 (7.5%)	27 (9.1%)	1 (2%)	0 (0%)	
Intra peritoneal oxaliplatin					0.14
No	231 (43.2%)	180 (41.2%)	34 (51.5%)	17 (53.1%)	
Yes	304 (56.8%)	257 (58.8%)	32 (48.5%)	15 (46.9%)	
Adjuvant CT post-HIPEC					0.0026
No	234 (44.9%)	176 (41.5%)	42 (63.6%)	16 (51.6%)	
Yes	287 (55.1%)	248 (58.5%)	24 (36.4%)	15 (48.4%)	
Monoclonal antibodies post-HIPEC					0.29
No	461 (86.2%)	373 (85.4%)	61 (92.4%)	27 (84.4%)	

Yes	74 (13.8%)	64 (14.6%)	5 (7.6%)	5 (15.6%)	
Liver Metastases					
Number of LM (median [IQR])	1 [1-2]	1 [1-2]	1 [1-3]	2 [1-4]	0.46
N > 3	55 (13.1%)	33 (9.9%)	14 (23.7%)	8 (27.6%)	0.0008
Liver resection					0.36
R0	454 (92.8%)	370 (92.3%)	63 (96.9%)	21 (91.3%)	
R1	35 (7.2%)	31 (7.7%)	2 (3.1%)	2 (8.7%)	
Major hepatectomy*					0.00011
No	493 (92.3%)	413 (94.5%)	52 (81.8%)	28 (90.3%)	
Yes	41 (7.3%)	24 (5.2%)	14 (20.3%)	3 (12.5%)	
Adjuvant CT					0.35
No	187 (38.2%)	162 (39.5%)	17 (29.8%)	8 (34.8%)	
Yes	303 (61.8%)	248 (60.5%)	40 (70.2%)	15 (65.2%)	

PM: Peritoneal metastases; CT: systemic chemotherapy; CEA: Carcinoembryonic antigen; CA19.9: Carbohydrate Antigen; HIPEC: hyperthermic intraperitoneal chemotherapy; Monoclonal antibodies: bevacizumab or anti epidermal growth factor receptor (EGFR) in K-RAS wild-type tumors; PCI: peritoneal cancer index; CCR: completeness of cytoreductive surgery, 0: no visible residual disease; 1: residual disease ≤ 2.5 mm; 2: residual disease > 2.5 and ≤ 5 mm; CCR 3: residual disease > 5 mm; EPIC: early postoperative intraperitoneal chemotherapy; LM: liver metastases; R0 resection: margin width > 1 mm; R1 resection: margin width ≤ 1 mm; CT: systemic chemotherapy. *Major hepatectomy was defined as the liver resection of at least three hepatic segments.

Table 3. Postoperative Outcomes at 90-days, according to Clavien- Dindo Classification of patients with liver and peritoneal metastases from colorectal cancer treated by cytoreductive surgery and hypertermic intraperitoneal chemotherapy associated with liver resection.

Type of Complication	Global outcomes		Complications by procedures	
	No.	%	CRS + HIPEC	Liver surgery
Details of postoperative complications	317	59.4%		
Hemoperitoneum	29	9.2%		
Global anastomotic leak	78	24.6%		
Enteric fistula	41	12.9%		
Pancreatic fistula	8	2.5%		
Biliary leak	10	3.2%		
Urinary fistula	16	5%		
Other	3	0.9%		
Intra-abdominal abscess	42	13%		
Wound infection	14	0.44%		
Peritonitis	3	0.9%		
Pleural effusion with drainage	45	14.2%		
Pneumonia	16	5%		
Respiratory distress	5	0.3%		
Pulmonary embolism	2	0.1%		
Ileus	5	0.3%		
Complications (Clavien Dindo)*				
0			217 (40.6%)	515 (96.4%)
1			54 (10.1%)	8 (1.5%)
2			87 (16.3%)	2 (0.4%)
3			19 (3.6%)	2 (0.4%)
3a			56 (10.5%)	3 (0.6%)
3b			45 (8.4%)	0 (0%)
4			48 (8.9%)	3 (0.6%)
5			8 (1.5%)	1 (0.18%)
90-day postoperative major complications (grade III-IV)	176	32.9%		
Reoperation				

No			485 (86.5%)	61 (93.8%)
Yes			76 (13.5%)	4 (6.2%)
Mortality	23	4%		
90 days mortality				
No			539 (96.8%)	78 (94%)
Yes			18 (3.2%)	5 (6%)
Hospital stay (days)	23		22.9 (+/- 14.6)	14.1 (+/- 13.5)

* Dindo D, Demartines N, Clavien PA: Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205-13, 2004.

Table 4. Univariate analysis of risk factors for complications of patients treated by cytoreductive surgery and hypertermic intraperitoneal chemotherapy associated with liver resection for liver and peritoneal metastases from colorectal cancer.

	OR [95% CI]	p value
Age	0.99 [0.98-1.01]	0.23
Age > 60 years		0.41
No	1	
Yes	0.85 [0.58-1.24]	
Treatment after year 2000*		0.3
No	1	
Yes	0.68 [0.34-1.42]	
PCI (for each more point)	1.03 [1.01-1.06]	0.0084
PCI > 12		0.007
No	1	
Yes	1.73 [1.16-2.56]	
EPIC		0.36
No	1	
Yes	1.21 [0.52-2.67]	
Intraperitoneal Oxaliplatin		0.041
No	1	
Yes	0.69 [0.48-0.99]	
Neoadjuvant CT for PM		0.31
No	1	
Yes	1.26 [0.81-1.98]	
Number of LM	1.00 [0.88-1.13]	0.98
> 3 LM		0.88
No	1	
Yes	1.05 [0.56-1.9]	
Major hepatectomy		0.77
No	1	
Yes	1.11 [0.54-2.21]	

PCI: peritoneal cancer index; EPIC: early postoperative intraperitoneal chemotherapy; CT: systemic chemotherapy; PM: Peritoneal metastases; LM: Liver metastases; Major hepatectomy was defined as the liver resection of at least three hepatic segments. *Treatment after year 2000: the analysis was stratified by time periods (before and after 2000) to discern the effect of modern oxaliplatin-based.

Table 5. Uni and multivariable analysis for Overall Survival of patients treated by cytoreductive surgery and hypertermic intraperitoneal chemotherapy associated with liver resection for liver and peritoneal metastases from colorectal cancer.

	Univariate analysis		Multivariate analysis	
	HR [95% CI]	p value	HR [95% CI]	p value
Age	1 [0.99-1.01]	0.55		
Age > 60 years		0.29		
No	1			
Yes	0.87 [0.67-1.13]			
Gender		0.84		
Female	1			
Male	1.03 [0.8-1.32]			
Primary Tumor side		0.46		
Right	1			
Left	0.81 [0.62-1.05]			
Rectum	0.93 [0.64-1.38]			
Multifocal	0.88 [0.22-3.57]			
Primary tumor Differentiation		0.49		
Good	1			
Moderate	1.04 [0.72-1.51]			
Poor	1.27 [0.82-1.95]			
T from the TNM		0.39		
T3	1			
T1 or T2	1.69 [0.78-3.66]			
T4	1.07 [0.79-1.44]			
N from the TNM		0.1		0.087
N0	1		1	
N1	1.33 [0.9-1.96]		1.36 [0.89-2.06]	
N2N3	1.52 [1.03-2.23]		1.57 [1.04-2.37]	
Treatment after year 2000*		0.066		
No	1			
Yes	0.69 [0.47-1.03]			
Surgical Sequences		0.036		NS
One step	1			
Liver first	0.6 [0.41-0.89]			
HIPEC first	0.89 [0.55-1.42]			
Sequence		0.02		NS
One step	1			
Two steps	0.69 [0.5-0.95]			
PCI (for each more point)	1.05 [1.04-1.07]	<0.0001	1.07 [1.05-1.09]	<0.0001
PCI > 12		<0.0001		NS
No	1			
Yes	1.98 [1.53-2.56]			
CCR		0.66		
0	1			
1	1.09 [0.76-1.56]			

EPIC		0.4		
No	1			
Yes	1.21 [0.77-1.91]			
Intraperitoneal Oxaliplatin		0.07		NS
No	1			
Yes	0.8 [0.63-1.02]			
Neoadjuvant CT for PM		0.79		
No	1			
Yes	0.96 [0.73-1.28]			
Adjuvant CT for PM		0.5		
No	1			
Yes	0.92 [0.72-1.17]			
Number of LM	1.04 [0.96-1.12]	0.38		
More than 3 LM		0.34		
No	1			
Yes	1.21 [0.81-1.81]			
Major hepatectomy		0.65		
No	1			
Yes	0.9 [0.58-1.41]			
Liver resection		0.47		
R0	1			
R1	0.8 [0.44-1.46]			
Adjuvant CT after liver resection		0.0081		0.15
No	1		1	
Yes	0.71 [0.55-0.92]		0.8 [0.59-1.08]	

HIPEC: hyperthermic intraperitoneal chemotherapy; PCI: peritoneal cancer index; CCR: completeness of cytoreductive surgery, 0: no visible residual disease; 1: residual disease ≤ 2.5 mm; 2: residual disease > 2.5 and ≤ 5 mm; CCR 3: residual disease > 5 mm; EPIC: early postoperative intraperitoneal chemotherapy; CT: systemic chemotherapy; PM: Peritoneal metastases; LM: Liver metastases; Major hepatectomy was defined as the liver resection of at least three hepatic segments; R0 resection: margin width > 1 mm; R1 resection: margin width ≤ 1 mm; NS: Not significant. *Treatment after year 2000: the analysis was stratified by time periods (before and after 2000) to discern the effect of modern oxaliplatin-based.

Table 6. Uni and multivariable analysis for Relapse-free Survival of patients treated by cytoreductive surgery and hypertermic intraperitoneal chemotherapy associated with liver resection for liver and peritoneal metastases from colorectal cancer.

	Univariate analysis		Multivariate analysis	
	HR [95% CI]	p value	HR [95% CI]	p value
Age	1 [0.99-1.01]	0.85		
Age > 60 years		0.84		
No	1			
Yes	1.02 [0.84-1.24]			
Gender		0.30		
Female	1			
Male	1.11 [0.92-1.33]			
Primary Tumor side		0.0035		0.047
Right	1		1	
Left	0.89 [0.72-1.09]		0.95 [0.76-1.17]	
Rectum	0.92 [0.68-1.25]		1.00 [0.73-1.36]	
Multifocal	3.29 [1.53-7.05]		4.69 [1.90-11.57]	
Primary tumor Differentiation		0.65		
Good	1			
Moderate	0.99 [0.76-1.3]			
Poor	0.88 [0.63-1.23]			
T from the TNM		0.8		
T3	1			
T1 or T2	1.23 [0.67-2.27]			
T4	1 [0.8-1.25]			
N from the TNM		0.54		
N0	1			
N1	1.16 [0.88-1.52]			
N2N3	1.1 [0.84-1.46]			
Treatment after year 2000*		0.78		
No	1			
Yes	1.05 [0.73-1.53]			
Surgical Sequences		0.016		0.0071
One step	1		1	
Liver first	0.68 [0.51-0.9]		0.66 [0.49-0.87]	
HIPEC first	0.82 [0.55-1.21]		0.79 [0.52-1.19]	
Sequence		0.0063		NS
One step	1			
Two steps	0.72 [0.57-0.91]			
PCI (for each more point)	1.02 [1.01-1.04]	0.00038	1.02 [1.01-1.04]	0.0018
PCI > 12		0.0012		NS
No	1			
Yes	1.4 [1.14-1.72]			
EPIC		0.58		

No	1	
Yes	0.89 [0.6-1.33]	
Intraperitoneal Oxaliplatin		0.96
No	1	
Yes	1.01 [0.83-1.21]	
Neoadjuvant CT for PM		0.26
No	1	
Yes	1.14 [0.91-1.43]	
Adjuvant CT for PM		0.26
No	1	
Yes	1.14 [0.91-1.43]	
Number of LM	1.06 [0.99-1.12]	0.081
More than 3 LM		0.1
No	1	
Yes	1.28 [0.95-1.72]	
Major hepatectomy		0.24
No	1	
Yes	0.81 [0.57-1.15]	
Liver resection		0.11
R0	1	
R1	1.34 [0.93-1.92]	
Adjuvant CT after liver resection		0.12
No	1	
Yes	0.85 [0.7-1.04]	

HIPEC: hyperthermic intraperitoneal chemotherapy; PCI: peritoneal cancer index; CCR: completeness of cytoreductive surgery, 0: no visible residual disease; 1: residual disease ≤ 2.5 mm; 2: residual disease > 2.5 and ≤ 5 mm; CCR 3: residual disease > 5 mm; EPIC: early postoperative intraperitoneal chemotherapy; CT: systemic chemotherapy; PM: Peritoneal metastases; LM: Liver metastases; Major hepatectomy was defined as the liver resection of at least three hepatic segments; R0 resection: margin width > 1 mm; R1 resection: margin width ≤ 1 mm; NS: Not significant.

*Treatment after year 2000: the analysis was stratified by time periods (before and after 2000) to discern the effect of modern oxaliplatin-based.